Skip to main content

Table 1 Correlation between PAFAH1B3 expression and different clinicopathological Characteristics of clinical LUAD patients

From: PAFAH1B3 predicts poor prognosis and promotes progression in lung adenocarcinoma

Characteristics n PAFAH1B3 Pearson χ2 P value
Low or no expression High expression
Total 79 25(31.6) 54(68.4)   
Age(y)
 <60 39 13(33.3) 26(66.7) 0.101 0.75
  ≥ 60 40 12(30.0) 28(70.0)   
Gender
 Male 41 13(31.7) 28(68.3) 0.000 0.990
 Female 38 12(31.6) 26(68.4)   
Primary tumor
 T1 20 5(25.0) 15(75.0) 0.835 0.659
 T2 38 14(36.8) 24(63.2)   
 T3 + T4 18 6(33.3) 12(66.7)   
 Unknown 3 0(0.0) 3(100.0)   
Lymph node metastasis
 No 38 15(39.5) 23(60.5) 1.874 0.171
 Yes 40 10(25.0) 30(75.0)   
 Unknown 1 0(0.0) 1(100.0)   
Distant metastasis
 No 64 24(37.5) 40(62.5) 5.341 0.021*
 Yes 15 1(6.7) 14(93.3)   
TNM stage
 stage I 19 11(57.9) 8(42.1) 11.47 0.009**
 stage II 19 4(21.1) 15(78.9)   
 stage III 26 9(34.6) 17(65.4)   
 stage IV 15 1(6.7) 14(93.3)   
Vital status
 Alive 30 14(46.7) 16(53.3) 5.045 0.025*
 Dead 49 11(22.4) 38(77.6)   
  1. *P < 0.05, **P < 0.01